MM remains an incurable malignancy requiring novel strategies for treatment of relapsed disease. BCMA targeted CAR T cell therapies stemming from our group and others induce frequent and deep responses in heavily pre-treated patients with limited treatment options. Despite these encouraging results, relapses still occur commonly. This lecture will address the development and results of BCMA targeted CAR T cell therapy, and approaches we are evaluating in the lab to address mechanisms of resistance limiting the durability of responses.
(Refreshments will be served at 9:45 am)